Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 16/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TLR4 | O00206 | 1/20 | 0.49 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8263806 | 1.00 | ADRB3 (0.65) | ADRB3ADRB1ADRB2DNM1LMNA | |
| SCHEMBL4902486 | 1.00 | ADRB3 (0.65) | ADRB3ADRB1ADRB2DNM1LMNA | |
| SCHEMBL5257329 | 0.88 | ADRB3 (0.66) | ADRB3ADRB1ADRB2DNM1LMNA | |
| SCHEMBL8266605 | 0.87 | ADRB3 (0.62) | ADRB3ADRB1ADRB2DNM1LMNA | |
| SCHEMBL8262374 | 0.85 | ADRB2 (0.48) | ADRB3ADRB1ADRB2DNM1LMNA | |
| SCHEMBL14023045 | 0.85 | ADRB3 (0.49) | ADRB3ADRB1LMNAKDM4EMAPT | |
| SCHEMBL2995902 | 0.83 | ADRB2 (0.68) | ADRB3ADRB1ADRB2DNM1LMNA | |
| SCHEMBL2991050 | 0.83 | ABCB1 (0.62) | ADRB3ADRB1ADRB2DNM1ABCB1 | |
| SCHEMBL2999158 | 0.83 | ADRB3 (0.60) | ADRB3ADRB1ADRB2DNM1LMNA | |
| SCHEMBL8182207 | 0.82 | ADRB2 (0.52) | ADRB3ADRB1ADRB2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ARTESIAN THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1833480-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | Artesian Therapeutics, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006060122-A9 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS INC (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006060122-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ADRB3, PDE3A, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.